MedPage Today on MSN
Overcoming CDK4/6 inhibitor resistance in HR-positive/HER2-negative breast cancer
The optimal approach to treatment in the post-CDK4/6 inhibitor setting remains undefined, but multiple strategies have ...
Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, ...
Rb1 loss may serve as a predictive biomarker to guide new targeted therapies for select breast cancers resistant to standard ...
Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic ...
MIAMI BEACH -- Emerging data have helped optimize the use of CDK4/6 inhibitors in metastatic hormone receptor (HR)-positive breast cancer, and the focus has turned to overcoming resistance, a breast ...
Tukysa, combined with Herceptin and Perjeta, extends progression-free survival in HER2+ metastatic breast cancer, showing ...
Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation. Stay ahead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback